請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85275完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 簡國龍(Kuo-Liong Chien) | |
| dc.contributor.author | Hsin-Mei Yeh | en |
| dc.contributor.author | 葉新美 | zh_TW |
| dc.date.accessioned | 2023-03-19T22:54:32Z | - |
| dc.date.copyright | 2022-10-03 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-07-29 | |
| dc.identifier.citation | 1. Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990–2019: update from the GBD 2019 study. Journal of the American College of Cardiology. 2020;76(25):2982-3021. 2. Armenian SH, Xu L, Ky B, et al. Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study. Journal of Clinical Oncology. 2016;34(10):1122-1130. 3. Koene RJ, Prizment AE, Blaes A, Konety SH. Shared risk factors in cardiovascular disease and cancer. Circulation. 2016;133(11):1104-1114. 4. Logan V, Leedy D, Masri SC, Cheng RK. Cardiovascular disease and cancer: is there increasing overlap? Current Oncology Reports. 2019;21(6):47. 5. Kravchenko J, Berry M, Arbeev K, Lyerly HK, Yashin A, Akushevich I. Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. Lung Cancer. 2015;88(1):85-93. 6. Rivera DH, Gómez JN-G, de Bobadilla JCF, et al. Cardiovascular disease and survival in non-small cell lung cancer: A multicenter prospective assessment. Clinical and Translational Oncology. 2019;21(9):1220-1230. 7. Curigliano G, Lenihan D, Fradley M, et al. Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations. Annals of Oncology. 2020;31(2):171-190. 8. Lange SA, Reinecke H. Coronary Artery Disease and Cancer: Treatment and Prognosis Regarding Gender Differences. Cancers. 2022;14(2):434. 9. Han X-J, Li J-Q, Khannanova Z, Li Y. Optimal management of coronary artery disease in cancer patients. Chronic Diseases and Translational Medicine. 2019;5(04):221-233. 10. DiPiro JT, Talbert RL, Yee GC, Matzke GR, Wells BG, Posey L. Pharmacotherapy: A Pathophysiologic Approach. 10th ed. McGraw-Hill Education; 2017. 11. Ettinger DS, Wood DE, Aisner DL, et al. Non–small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network. 2017;15(4):504-535. 12. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA: A Cancer Journal for Clinicians. 2015;65(1):5-29. 13. National Health Insurance Administration MoHW. Cancer Registry Annual Report 2018. Ministry of Health and Welfare Taipei, Taiwan; 2022. 14. Soria J-C, Mauguen A, Reck M, et al. Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Annals of Oncology. 2013;24(1):20-30. 15. Normanno N, De Luca A, Bianco C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006;366(1):2-16. 16. Zhang Y-L, Yuan J-Q, Wang K-F, et al. The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis. Oncotarget. 2016;7(48):78985. 17. Rennert G, Gottfried M, Rennert HS, et al. Long term follow-up of EGFR mutated NSCLC cases. Translational Oncology. 2021;14(1):100934. 18. Mok TS, Wu Y-L, Thongprasert S, et al. Gefitinib or carboplatin–paclitaxel in pulmonary adenocarcinoma. New England Journal of Medicine. 2009;361(10):947-957. 19. Yang J, Zhou Q, Yan H, et al. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. British Journal of Cancer. 2017;116(5):568-574. 20. Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Annals of Oncology. 2015;26(9):1883-1889. 21. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. The Lancet Oncology. 2012;13(3):239-246. 22. Gridelli C, Ciardiello F, Gallo C, et al. First-line erlotinib followed by second-line cisplatin-gemcitabine chemotherapy in advanced non-small-cell lung cancer: the TORCH randomized trial. Journal of Clinical Oncology. 2012;30(24):3002-3011. 23. Zhou C, Wu Y-L, Chen G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. The Lancet Oncology. 2011;12(8):735-742. 24. Lee CK, Wu Y-L, Ding PN, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis. Journal of Clinical Oncology. 2015;33(17):1958-1965. 25. Girard N. Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? Future Oncology. 2018;14(11):1117-1132. 26. Moore RA, Adel N, Riedel E, et al. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. Journal of Clinical Oncology. 2011;29(25):3466. 27. Zamorano JL, Lancellotti P, Rodriguez Munoz D, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(36):2768-2801. 28. Oyakawa T, Iida K, Kusuhara M, Kenmotsu H, Sugino T. Chemotherapy-induced cardiomyopathy caused by Pemetrexed. Investigational New Drugs. 2018;36(1):147-150. 29. Humphreys BD, Sharman JP, Henderson JM, et al. Gemcitabine‐associated thrombotic microangiopathy. Cancer. 2004;100(12):2664-2670. 30. Sandler A, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non–small-cell lung cancer. Journal of Clinical Oncology. 2000;18(1):122-122. 31. Oakes WM, Reed E, Gibbs H, Greenfield RA, Montello M. A reassessment of cardiac toxicity associated with Taxol. Journal of the National Cancer Institute: Monographs. 1990;(15):117. 32. Trimble E, Adams J, Vena D, et al. Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. Journal of Clinical Oncology. 1993;11(12):2405-2410. 33. Lapeyre‐Mestre M, Gregoire N, Bugat R, Montastruc JL. Vinorelbine‐related cardiac events: A meta‐analysis of randomized clinical trials. Fundamental & Clinical Pharmacology. 2004;18(1):97-105. 34. Gebbia V, Galetta D, Caruso M, et al. Gemcitabine and cisplatin versus vinorelbine and cisplatin versus ifosfamide+ gemcitabine followed by vinorelbine and cisplatin versus vinorelbine and cisplatin followed by ifosfamide and gemcitabine in stage IIIB–IV non small cell lung carcinoma: a prospective randomized phase III trial of the Gruppo Oncologico Italia Meridionale. Lung Cancer. 2003;39(2):179-189. 35. Makki N, Thiel KW, Miller FJ. The epidermal growth factor receptor and its ligands in cardiovascular disease. International Journal of Molecular Sciences. 2013;14(10):20597-20613. 36. Forrester SJ, Kawai T, O'Brien S, Thomas W, Harris RC, Eguchi S. Epidermal Growth Factor Receptor Transactivation: Mechanisms, Pathophysiology, and Potential Therapies in the Cardiovascular System. Annu Rev Pharmacol Toxicol. 2016;56:627-653. doi:10.1146/annurev-pharmtox-070115-095427 37. Zeboudj L, Giraud A, Guyonnet L, et al. Selective EGFR (Epidermal Growth Factor Receptor) Deletion in Myeloid Cells Limits Atherosclerosis—Brief Report. Arteriosclerosis, Thrombosis, and Vascular Biology. 2018;38(1):114-119. 38. Li W, Fang Q, Zhong P, et al. EGFR inhibition blocks palmitic acid-induced inflammation in cardiomyocytes and prevents hyperlipidemia-induced cardiac injury in mice. Scientific Reports. 2016;6(1):1-13. 39. Peng K, Tian X, Qian Y, et al. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II. Journal of Cellular and Molecular Medicine. 2016;20(3):482-494. 40. Shah S, Akhtar MS, Hassan MQ, Akhtar M, Paudel YN, Najmi AK. EGFR tyrosine kinase inhibition decreases cardiac remodeling and SERCA2a/NCX1 depletion in streptozotocin induced cardiomyopathy in C57/BL6 mice. Life Sciences. 2018;210:29-39. 41. Luo W, Huang L, Wang J, et al. Inhibition of EGFR-STAT3 attenuates cardiomyopathy in streptozotocin-induced type 1 diabetes. Journal of Endocrinology. 2019;242(3):199-210. 42. Shraim BA, Moursi MO, Benter IF, Habib AM, Akhtar S. The Role of Epidermal Growth Factor Receptor Family of Receptor Tyrosine Kinases in Mediating Diabetes-Induced Cardiovascular Complications. Frontiers in Pharmacology. 2021:1928. 43. Chen MH, Kerkelä R, Force T. Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation. 2008;118(1):84-95. 44. Shah RR, Morganroth J, Shah DR. Cardiovascular safety of tyrosine kinase inhibitors: with a special focus on cardiac repolarisation (QT interval). Drug Safety. 2013;36(5):295-316. 45. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR. New England Journal of Medicine. 2010;362(25):2380-2388. 46. Han J-Y, Park K, Kim S-W, et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. Journal of Clinical Oncology. 2012;30(10):1122-1128. 47. Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. The Lancet Oncology. 2010;11(2):121-128. 48. Soria J-C, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced non–small-cell lung cancer. New England Journal of Medicine. 2018;378(2):113-125. 49. Wu Y-L, Cheng Y, Zhou X, et al. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2017;18(11):1454-1466. 50. Moore MJ, Goldstein D, Hamm J, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. Journal of Clinical Oncology. 2007;25(15):1960-1966. 51. Srikanthan A, Ethier J-L, Ocana A, Seruga B, Krzyzanowska MK, Amir E. Cardiovascular toxicity of multi-tyrosine kinase inhibitors in advanced solid tumors: a population-based observational study. PLoS One. 2015;10(3):e0122735. 52. National Health Insurance Administration MoHW. National Health Insurance Annual Report 2014–2015. Ministry of Health and Welfare Taipei, Taiwan; 2014. 53. Chiang C-J, Wang Y-W, Lee W-C. Taiwan's nationwide cancer registry system of 40 years: past, present, and future. Journal of the Formosan Medical Association. 2019;118(5):856-858. 54. Chiang C-J, You S-L, Chen C-J, Yang Y-W, Lo W-C, Lai M-S. Quality assessment and improvement of nationwide cancer registration system in Taiwan: a review. Japanese Journal of Clinical Oncology. 2015;45(3):291-296. 55. Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nature Reviews Rheumatology. 2015;11(7):437-441. 56. Savikko J, Rintala JM, Rintala S, Koskinen P. Epidermal growth factor receptor inhibition by erlotinib prevents vascular smooth muscle cell and monocyte–macrophage function in vitro. Transplant Immunology. 2015;32(3):175-178. 57. Heliste J, Jokilammi A, Vaparanta K, Paatero I, Elenius K. Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia. Scientific Reports. 2021;11(1):1-16. 58. Sun X, Liang J, Yao X, et al. The activation of EGFR promotes myocardial tumor necrosis factor-α production and cardiac failure in endotoxemia. Oncotarget. 2015;6(34):35478. 59. Ghatge M, Nair J, Sharma A, Vangala RK. Integrative gene ontology and network analysis of coronary artery disease associated genes suggests potential role of ErbB pathway gene EGFR. Molecular Medicine Reports. 2018;17(3):4253-4264. 60. Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer management and research. 2015;7:133. 61. Buza V, Rajagopalan B, Curtis AB. Cancer treatment–induced arrhythmias: focus on chemotherapy and targeted therapies. Circulation: Arrhythmia and Electrophysiology. 2017;10(8):e005443. 62. Copenhagen BCSDC. Who needs the Cox model anyway. Stat Med. 2012;31:1074-1088. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85275 | - |
| dc.description.abstract | 背景 關於表皮生長因子受體酪氨酸激酶抑製劑（EGFR-TKI）與心血管疾病風險之間的關係仍然不明。本研究旨在評估臺灣晚期非小細胞肺癌患者接受EGFR-TKI治療後的心血管事件。 方法 本研究納入2011年至2016年期間接受EGFR-TKI或化學治療（化療）的新診斷晚期非小細胞肺癌患者，並追蹤至2018年。資料來自台灣癌症登記長表資料庫及全民健康保險研究資料庫。主要探討的心血管事件為冠狀動脈疾病，使用住院診斷碼、手術處置碼及死因定義。其他原因導致的死亡被視為競爭風險。利用Cox迴歸模型獲得多變項調整之特定原因的風險比率及其95%信賴區間比較接受EGFR-TKI（n= 15205；EGFR-TKI世代）和接受化療（n= 10614；化療世代）的患者發生冠狀動脈疾病的風險。 結果 在中位數為0.7年的追蹤期間，25,819位晚期非小細胞肺癌患者共發生397起冠狀動脈疾病。冠狀動脈疾病的發病率在EGFR-TKI世代為每千人年10.0例，在化療世代為每千人年19.1例。與接受化療的患者相比，接受 EGFR-TKI 的患者調整後的冠狀動脈疾病風險比率為0.65；95%信賴區間為0.52至0.81。心臟保護的效果在男性和非吸煙者中更為明顯。 結論 與化療相比，晚期非小細胞肺癌患者接受EGFR-TKI可降低心血管疾病的風險。尚須進一步的研究探討EGFR在心血管系統中的作用。 | zh_TW |
| dc.description.abstract | Introduction Evidence regarding the relationship between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and the risk of cardiovascular disease (CVD) is limited. This study aimed to evaluate the incident cardiovascular outcomes of patients with advanced non-small-cell lung cancer (NSCLC) treated with EGFR-TKIs in Taiwan. Methods Patients with newly diagnosed advanced NSCLC who received EGFR-TKI or chemotherapy between 2011 and 2016 were enrolled and followed up until 2018. Data were extracted from administrative databases. The primary outcome of interest was coronary artery disease (CAD). Death from other causes was considered a competing risk. We compared the risk of incident CAD between participants receiving EGFR-TKI (n= 15205; EGFR-TKI cohort) and chemotherapy (n= 10614; chemotherapy cohort) using multivariable-adjusted cause-specific hazard ratios (cause-specific HR) with 95% confidence intervals (CI) obtained from Cox’s regression model. Results A total of 397 CAD events occurred in 25,819 participants with advanced NSCLC during a median follow-up of 0.7 years. The incidence rates of CAD were 10.0 cases per 1,000 person-years in the EGFR-TKI cohort and 19.1 cases per 1,000 person-years in the chemotherapy cohort. The adjusted cause-specific HR of CAD in those who received EGFR-TKI was 0.65 (95% CI, 0.52-0.81), compared with those who received chemotherapy. The cardioprotective effect was more pronounced in men and non-smokers. Conclusion EGFR-TKI may reduce the risk of CVDs in patients with advanced NSCLC compared with chemotherapy. Further investigations on the EGFR-specific mechanisms related to the cardiovascular system are warranted. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T22:54:32Z (GMT). No. of bitstreams: 1 U0001-2907202215552500.pdf: 2577852 bytes, checksum: 6c134bc1bf76de9678eacfd89e840343 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 口試委員審定書---i 誌謝---ii 摘要---iii Abstract---iv Table of Contents---vi List of Figures---viii List of Tables---ix Chapter 1 Background---1 1.1 Importance of cardiovascular diseases (CVDs) in lung cancer---1 1.2 Treatment options in advanced non-small-cell lung cancer (NSCLC)---1 1.3 Potential biological mechanisms of CVD risk in the systemic therapy of advanced NSCLC---3 1.4 Research gap---8 Chapter 2 Study hypothesis and aims---10 Chapter 3 Methods---11 3.1 Data sources---11 3.2 Study design and participants---12 3.3 Exposure assessments---13 3.4 Incident CVD assessments---13 3.5 Definitions of baseline comorbidities and covariates---14 3.6 Statistical analyses---15 Chapter 4 Results---18 4.1 Baseline characteristics of the current study cohorts---18 4.2 Time-to-CAD event distributions of the study cohorts---19 4.3 The incidence rate of CVDs in the study cohorts---19 4.4 The association between EGFR-TKI treatment and CVD---21 Chapter 5 Discussion---24 5.1 Main findings---24 5.2 Comparisons with previous studies---24 5.3 Biological mechanisms---25 5.4 Clinical and public health implication---26 5.5 Strengths and weakness---27 5.6 Conclusion---28 References---29 Appendices---62 Appendix A: 口試問題與回答 (依問題性質歸類)---62 Appendix B: SAS code---65 | |
| dc.language.iso | en | |
| dc.title | 晚期非小細胞肺癌患者使用表皮生長因子受體酪氨酸激酶抑製劑與心血管疾病風險的關係 | zh_TW |
| dc.title | Association between Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors and the Risk of Cardiovascular Diseases in Advanced Non-Small Cell Lung Cancer | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.advisor-orcid | 簡國龍(0000-0003-4979-8351) | |
| dc.contributor.oralexamcommittee | 杜裕康(Yu-Kang Tu),李文宗(Wen-Chung Lee),張淑惠(Shu-Hui Chang),林家齊(Chia-Chi Lin) | |
| dc.subject.keyword | 表皮生長因子受體酪氨酸激酶抑製劑,EGFR-TKI,心血管疾病,冠狀動脈疾病, | zh_TW |
| dc.subject.keyword | epidermal growth factor receptor tyrosine kinase inhibitors,EGFR-TKI,cardiovascular diseases,coronary artery disease,stroke, | en |
| dc.relation.page | 107 | |
| dc.identifier.doi | 10.6342/NTU202201880 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-07-30 | |
| dc.contributor.author-college | 公共衛生學院 | zh_TW |
| dc.contributor.author-dept | 流行病學與預防醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-10-03 | - |
| 顯示於系所單位： | 流行病學與預防醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-2907202215552500.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 2.52 MB | Adobe PDF | 檢視/開啟 |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。